Are injections likely to help my knee or hip pain

Injections are most often discussed when knee or hip osteoarthritis (OA) has been diagnosed and pain or stiffness is still “getting in the way” despite a reasonable spell of basics such as activity modification, strengthening work, weight management where relevant, and simple pain relief. In the UK, NHS information also notes that symptoms and X‑ray changes can be mismatched, so the deciding factor is usually what the joint is stopping someone from doing day to day rather than the scan report alone.

For symptom control, the strongest guideline backing is for steroid (glucocorticoid) injections. The 2019 American College of Rheumatology/Arthritis Foundation guideline strongly recommends intra‑articular glucocorticoid injections for knee and hip OA, alongside measures like exercise, weight loss in overweight patients, and education/self‑management. Large reviews describe these injections as helping pain in the short term rather than changing the underlying arthritis.

Timing matters. A 2024 meta‑analysis of 11 randomised trials in knee OA found clinically meaningful improvements in pain and function mainly up to 6 weeks, smaller benefits out to about 3 months, and no clear benefit versus placebo by 6 months. A guideline-focused review similarly describes steroid benefit as relatively short-lived (often under 4 weeks) and advises caution with repeated injections because of potential harm.

In practice, injections tend to come up after a flare that has not settled with topical or oral anti‑inflammatories (where safe), or when pain is disrupting walking, stairs, sleep, work, or caring responsibilities—sometimes with a fixed event (for example, travel) where a temporary improvement would be valuable. For hip OA, intra‑articular steroid injections are widely used, and a 2013 report describes ultrasound guidance as an accurate and safe alternative to landmark or fluoroscopy-based approaches.

What good conservative care looks like before injections

Before any injection is on the table, most guidance treats osteoarthritis care as a stepwise pathway in which conservative (non‑surgical) management comes first. A 2022 review of knee OA notes that conservative care is conventionally first‑line to help avoid or delay surgery, but is often under‑used or applied inconsistently—so some people never get a complete, joined‑up plan in the first place. To keep this section readable, the supporting evidence is referenced separately rather than appearing as raw web-link strings in the body text.

Across major sources (including the 2019 American College of Rheumatology/Arthritis Foundation guideline and a 2021 review by Katz and colleagues), the “core package” tends to look similar: a structured exercise programme, weight loss where relevant, education/self‑management support, and careful use of pain medicines such as topical/oral NSAIDs when safe.

“Structured exercise” generally means more than just trying to “keep active”. In the 2019 ACR/AF guideline, exercise is a strongly recommended treatment, and the 2021 Katz review puts prescribed exercise at the centre of care. In practice, this usually translates into a progressive strengthening plan (often hip and thigh strength for knee OA; hip strength and mobility for hip OA), plus regular low‑impact aerobic work such as walking or cycling, ideally with progression and review rather than one‑off advice.

Weight management is also repeatedly highlighted, including as a strong recommendation in the 2019 ACR/AF guideline for people with knee and/or hip OA who are overweight. NHS osteoarthritis guidance frames this as part of day‑to‑day symptom control (alongside staying active), and it tends to work best when paired with strengthening and pacing, rather than relying on dieting alone.

Self‑management is the other “hidden” cornerstone in NHS advice: pacing tasks on painful days, planning around flares, and using straightforward symptom tools (for example, heat/ice and simple supports) alongside appropriate pain relief. The 2021 Katz review also emphasises topical or oral NSAIDs where safe, as add‑ons to exercise/weight/education rather than replacements.

A conservative plan is usually considered to have had a fair trial when it includes (and is actually followed):

• a progressive strengthening and activity plan (as “prescribed exercise”, not just occasional activity)
• weight‑loss support if weight is a contributing factor
• an education/self‑management approach (pacing, flare plans, realistic activity goals)
• medicines used judiciously (for example topical/oral NSAIDs where appropriate), alongside the above rather than instead of it

Has conservative care really ‘failed’ in my case

The phrase “failed conservative care” can sound like a judgement, but in osteoarthritis it usually just means symptoms are still driving day-to-day limitation despite a proper run at non-surgical options. Reviews of knee OA (including a 2022 overview) also note that conservative care is often under-used or inconsistently delivered, so “failure” may sometimes reflect an incomplete programme rather than lack of effort or “willpower”.

Because research does not set a single time-limit or checklist, clinicians tend to make a whole-picture call. A practical way this is often framed in clinic is a simple three-part ‘ready to escalate?’ test:

• Consistency and time (weeks to months): there has been a sustained attempt (often several months) at an exercise-and-self-management plan, usually with GP and/or physiotherapy input, plus sensible adjustments to daily tasks during flares (NHS advice often centres on staying active, strengthening, pacing and pain relief).
• Impact (today, not on an X-ray): pain is still present most days, or there is ongoing difficulty with basics such as stairs, walking to the shops, standing at work, or sleep disturbance, despite those measures.
• Confidence in the diagnosis: symptoms and examination fit hip or knee OA (as described in the 2021 Katz review), with imaging used mainly as supportive context rather than the sole “severity score”; NHS Inform highlights that X-ray changes and symptom severity can mismatch in both hip and knee OA.

Where escalation goes next depends on the “gap” between symptoms and the next step. Injections are commonly considered when pain and function remain troublesome after a reasonable conservative trial, but joint replacement still feels too early or too drastic. Surgery tends to sit at a higher threshold: the Katz review describes candidates for total joint replacement as those with advanced symptoms plus structural damage who remain significantly impaired despite non-operative treatments.

Early hip osteoarthritis diagnosis and first‑line self‑management

Hip osteoarthritis is typically identified in the clinic rather than “diagnosed off a scan”. In the 2021 review by Katz and colleagues, the pattern is a combination of hip pain (often felt in the groin, but sometimes the buttock), stiffness and functional limitation, plus examination findings such as pain on internal rotation; an X-ray can then support the diagnosis with features like marginal osteophytes and joint-space narrowing rather than acting as a stand-alone severity score.

One reason early hip OA can feel confusing is that symptoms and imaging do not reliably match. NHS Inform’s hip osteoarthritis guidance notes that some people have marked osteoarthritic changes on X‑ray with mild symptoms, while others have severe pain and limitation with relatively little visible change. In practice, decisions about escalation are therefore driven mainly by pain, day-to-day function and what is found on examination, not by the word “mild” on a report.

First-line management still centres on keeping the hip moving and strong, alongside symptom control. Katz et al. describe prescribed exercise, weight loss where appropriate, and education as cornerstones of hip and knee OA care, complemented by topical or oral NSAIDs when safe; NHS osteoarthritis advice similarly emphasises staying active, strengthening around the joint, pacing tasks and using pain relief.

A typical early-stage hip plan (often set up with physiotherapy input) can include:

• hip-specific strengthening and control work (for example, progressive gluteal and hip abductor strengthening), plus mobility work that is tolerable day to day
• graded aerobic activity such as walking, cycling or pool exercise, with some high-impact activity (for example, running on hard ground) swapped for lower-impact options when symptoms flare
• pacing strategies on higher-load days (for example, planning lighter tasks or rest after a long walk), and simple supports when needed (such as using a handrail on stairs or a walking aid for longer distances)

Injections tend to enter the conversation when pain remains function-limiting despite a well-run exercise and self-management programme, or when short-term pain relief is needed to re-engage with rehabilitation. Katz et al. characterise intra-articular steroid injections as a short-term pain-relief tool rather than disease-modifying treatment, and a 2013 report describes ultrasound-guided hip steroid injection as a well-established approach with good accuracy and a favourable safety profile. For hip injections beyond steroids (such as hyaluronic acid or platelet-rich plasma), a 2025 review reports that many options can reduce pain and improve function, but also stresses that head-to-head comparisons and long-term outcomes remain limited.

How different injection options compare in knees and hips

In practice, injections tend to be chosen based on the job they need to do: short-term calming of a painful flare, a “window” to help rehabilitation along, or a longer stretch of symptom control when day-to-day pain is still limiting. Across major reviews (including Katz et al., 2021), these treatments sit alongside exercise, weight management where relevant and appropriate pain relief—not as disease-stopping therapies—and none has been proven to “halt” osteoarthritis in the hip or knee.

Corticosteroid (steroid) injections

The strongest guideline backing is for intra-articular glucocorticoids. The 2019 American College of Rheumatology/Arthritis Foundation guideline strongly recommends steroid injections for both knee and hip OA. For knee OA specifically, a 2024 meta-analysis of 11 randomised trials (842 people) found clinically meaningful improvements in pain and function mainly at short-term follow-up (≤6 weeks), smaller benefits up to about 3 months, and no discernible benefit versus placebo by 6 months—so this option is usually framed as a short-term symptom tool.

Safety is generally favourable when used judiciously, but repetition is where caution comes in. A guideline-focused review notes steroid benefit can be “relatively short lived (<4 weeks)” and advises care with repeated injections because of potential harm. Observational data cannot prove cause-and-effect, but a 48-month cohort study (189 patients) reported the fastest joint-space narrowing in the steroid-injection group, and faster narrowing in those receiving multiple injections compared with a single injection.

Hyaluronic acid (HA) injections

HA is often positioned as a “try for longer symptom relief” option in knee OA when simple measures and medicines have not been enough. The international guideline review reports HA can improve pain and function, with most positive outcomes linked to high–molecular-weight HA given in short courses (for example, 2–4 injections per year), although national guideline positions vary. For hip OA, a 2025 review describes HA as a potentially helpful option for pain and function, but stresses that long-term and head-to-head comparative evidence remains limited.

Platelet-rich plasma (PRP) and other biologic injections

PRP is usually discussed when the goal is a longer-lasting effect than steroids, accepting that the evidence base is less settled and protocols differ. In a 160-person knee OA trial (with symptoms despite conventional treatment), both PRP and HA improved outcomes at 12 months, with larger improvements in some measures for PRP—especially in moderate (grade 2) disease. A 2019–2024 systematic review comparing PRP with steroids concluded both are generally safe and effective, with some studies suggesting more sustained benefit from PRP, but heterogeneity and limited long-term follow-up prevent firm “best option” claims; many guidelines still do not recommend routine PRP for knee OA. In hip OA, the 2025 injection-therapy review also reports short-term pain and functional gains across several injectables (including PRP and cell-based products), while emphasising that robust comparisons and long-term outcomes are still sparse.

When injections aren’t enough and surgery enters the picture

Joint replacement tends to enter the picture when osteoarthritis symptoms remain strongly disabling despite a full run at non-surgical care and one or more appropriately chosen injections. In the 2021 review by Katz and colleagues, people with advanced symptoms and structural damage who are still significantly impaired after nonoperative treatment are described as candidates for total joint replacement—framing surgery as an escalation step rather than a “first answer”.

Many people sit in the middle for a long time: a consistent exercise and strengthening plan, weight management where relevant, education/self-management, and occasional injections can sometimes keep pain and function at a workable level for years. A 2022 review of knee OA also notes that conservative care is conventionally the first-line approach intended to avoid or delay surgery, even though it can be under-used in practice.

Patterns that often signal injections may no longer be enough include pain on most days (and sometimes at night), marked stiffness, shrinking walking distance, and difficulty with basics such as stairs, work tasks, or self-care—despite having tried appropriate non-surgical care and injections.

Referral for a surgical opinion does not commit anyone to an operation; it opens a detailed discussion of options and trade-offs. To avoid an advert-style finish, the closing next step is a general consultation checklist rather than a brand link:

• what activities are now limited (for example, walking distance or sleep)
• what changed (and for how long) after the last injection
• what imaging shows alongside the symptom picture
• whether further nonoperative optimisation or joint replacement is the realistic next step.

1. [1] The Current Status and Future Prospects of Intra-articular Injection Therapy for Hip Osteoarthritis: A Review. (2025). https://doi.org/10.1007/s11916-025-01378-z https://doi.org/10.1007/s11916-025-01378-z